PMID- 28806766
OWN - NLM
STAT- MEDLINE
DCOM- 20171009
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 8
DP  - 2017
TI  - Sublingual immunotherapy (SLIT) for house dust mites does not prevent new 
      allergen sensitization and bronchial hyper-responsiveness in allergic rhinitis 
      children.
PG  - e0182295
LID - 10.1371/journal.pone.0182295 [doi]
LID - e0182295
AB  - INTRODUCTION: The aim of this study is to identify the effects of sublingual 
      immunotherapy (SLIT) on immunologic parameters and bronchial-hyper-responsiveness 
      in children with allergic rhinitis to house-dust mite (HDM), through long-term 
      follow-up cohort. METHODS: Among the Allergic Rhinitis Cohort Study for Kids, 
      pediatric patients who visited the hospital for rhinitis symptoms and proven 
      allergy to HDM through skin prick test were studied. In this cohort, 37 patients 
      received SLIT more than 3-years (SLIT group), and 184 patients received only 
      pharmacologic therapy (non-SLIT group) were included in this study. The results 
      of skin prick test, eosinophil percent and count, total immunoglobulin E (IgE), 
      and bronchial provocation test at initial and 3-year followed-up were compared in 
      the two groups. RESULTS: After 3 year follow-up, only the serum eosinophil 
      percent decreased more significantly in SLIT group than that in the non-SLIT 
      group. New-sensitization rate other than HDM between SLIT and non-SLIT group did 
      not show any significant differences. The distribution of sensitized allergen 
      other than HDM showed increasing tendency after 3 years in both groups. Older age 
      and a small number of sensitized allergen affected the improvement of bronchial 
      hyper-responsiveness regardless of SLIT. CONCLUSION: HDM SLIT in allergic 
      rhinitis children for 3 years in Korea does not affect prevention of new 
      sensitization and poly-sensitization rate increment, and improvement of bronchial 
      hyper-responsiveness.
FAU - Lim, Jae Hyun
AU  - Lim JH
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National 
      University College of Medicine, Seoul National University Hospital, Seoul, Korea.
FAU - Kim, Jin Youp
AU  - Kim JY
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National 
      University College of Medicine, Seoul National University Hospital, Seoul, Korea.
FAU - Han, Doo Hee
AU  - Han DH
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National 
      University College of Medicine, Seoul National University Hospital, Seoul, Korea.
FAU - Lee, Chul Hee
AU  - Lee CH
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National 
      University College of Medicine, Seoul National University Hospital, Seoul, Korea.
FAU - Hong, Seung-No
AU  - Hong SN
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College 
      of Medicine, Korea University Ansan Hospital, Ansan, Korea.
FAU - Wee, Jee Hye
AU  - Wee JH
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Bundang Jesaeng General 
      Hospital, Deajin Medical Center, Seongnam, Korea.
FAU - Park, Sue K
AU  - Park SK
AD  - Department of Preventive Medicine, Seoul National University College of Medicine, 
      Seoul, Korea.
AD  - Department of Biomedical Science, Seoul National University Graduate School, 
      Seoul, Korea.
AD  - Cancer Research Institute, Seoul National University, Seoul, Korea.
FAU - Rhee, Chae-Seo
AU  - Rhee CS
AUID- ORCID: 0000-0002-1361-8585
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National 
      University College of Medicine, Seoul National University Bundang Hospital, 
      Seongnam, Korea.
AD  - Institute of Allergy and Clinical Immunology, Seoul National University Medical 
      Research Center, Seoul, Korea.
AD  - Sensory Organ Research Center, Seoul National University Medical Research Center, 
      Seoul, Korea.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20170814
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Allergens)
SB  - IM
MH  - Adolescent
MH  - Allergens/*immunology
MH  - Animals
MH  - Bronchial Hyperreactivity/blood/complications/*immunology/*therapy
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *Immunization
MH  - Incidence
MH  - Male
MH  - Pyroglyphidae/*immunology
MH  - Rhinitis, Allergic/blood/complications/*immunology/*therapy
MH  - Skin Tests
MH  - *Sublingual Immunotherapy
MH  - Treatment Outcome
PMC - PMC5555666
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2017/08/15 06:00
MHDA- 2017/10/11 06:00
PMCR- 2017/08/14
CRDT- 2017/08/15 06:00
PHST- 2017/05/16 00:00 [received]
PHST- 2017/07/14 00:00 [accepted]
PHST- 2017/08/15 06:00 [entrez]
PHST- 2017/08/15 06:00 [pubmed]
PHST- 2017/10/11 06:00 [medline]
PHST- 2017/08/14 00:00 [pmc-release]
AID - PONE-D-17-18758 [pii]
AID - 10.1371/journal.pone.0182295 [doi]
PST - epublish
SO  - PLoS One. 2017 Aug 14;12(8):e0182295. doi: 10.1371/journal.pone.0182295. 
      eCollection 2017.